Apnimed will present new research on drug candidates AD109 and AD113, targeting obstructive sleep apnea (OSA), at the European Respiratory Society’s (ERS) International Congress 2023.
For the first poster, the clinical-stage pharmaceutical company will present a new post-hoc analysis of data from the MARIPOSA phase 2b trial, a one-month efficacy, safety, and dose-finding study for AD109 (aroxybutynin/atomoxetine).
AD109, which has been granted Fast Track designation from the US Food and Drug Administration, is a potential first-in-class, novel, investigational combination dosed once daily at bedtime and is designed to treat OSA patients across a broad spectrum of disease severity. AD109 combines Apnimed’s novel selective antimuscarinic (aroxybutynin) with a selective norepinephrine reuptake inhibitor (atomoxetine). AD109 targets key neurological pathways in OSA that activate upper airway dilator muscles to maintain an open airway during sleep.
A second poster will also be presented on a small exploratory, proof-of-concept trial for another potential compound, AD113 (atomoxetine/mineralocorticoid receptor antagonist), exploring OSA severity and blood pressure in hypertensive patients.
“ERS 2023 is an opportunity to share the latest data on our investigational oral treatments for obstructive sleep apnea with respiratory experts from around the globe,” says Larry Miller, MD, CEO of Apnimed, in a release. “We are excited to be on the forefront of moving the science forward for potential pharmacologic options for OSA to support the millions of people around the world who are unable or unwilling to use currently available treatments.”
Presentation details:
Poster: PA1280
Session: 145 – Basic and clinical science in sleep breathing disorders: a bidirectional relationship
Time: Sunday, Sept 10, 12:30 to 14 CEST
Location: Allianz MiCo, PS-6 in poster area
Presenter: Luigi Taranto Montemurro, MD, chief scientific officer, Apnimed
Poster: PA3597
Session: 355 – From basic to translational sleep breathing disorders
Time: Monday, Sept 11, 16 to 17:30 CEST
Location: Allianz MiCo, PS-5 in poster area
Presenter: Ludovico Messineo, MD, PhD, associate professor ASN, Harvard Medical School
Photo 208437534 © Andrii Yalanskyi | Dreamstime.com
